HS-20090

DRUG2 trials

Sponsors

Jiangsu Hansoh Pharmaceutical Co., Ltd.

Conditions

Bone Metastasis From Solid TumorsHealthy

Phase 1

Comparing of the Pharmacokinetic, Pharmacodynamic, Safety and Immunogenicity of HS-20090 and Xgeva® in Healthy Adults

Jiangsu Hansoh Pharmaceutical Co., Ltd.Bone Metastasis From Solid Tumors

Start: 2020-09-01End: 2021-06-30Target: 154Updated: 2020-08-04

Comparing of the PK, PD, Safety and Immunogenicity of HS-20090 and Xgeva® in Healthy Adults

Jiangsu Hansoh Pharmaceutical Co., Ltd.Healthy

Start: 2023-04-20End: 2024-04-05Target: 180Updated: 2023-08-23

Related Papers

Biosimilarity of HS-20090 to Denosumab in healthy Chinese subjects: a randomized, double-blinded, pharmacokinetics/pharmacodynamics study

Expert Opinion on Investigational Drugs2022-09-165 citations